OKYO Pharma has been approved for a new patent titled, “Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents,” by the USPTO.
OKYO Pharma is in the business of finding solutions for ocular pains and diseases. With the use of G-Protein Coupled Receptor (GPCR) Platform technology, OKYO Pharma plans to produce therapies for inflammatory eye diseases and ocular pain management.
Following the patent update, the OKYO Pharma share price jumped 13.3% to trade at 8.5p.
With the patent issued today, OKYO is in position to develop the OK-101 drug. The OK-101 drug is in the pre-clinical phase currently. OK-101 is the lead compound for OKYO Pharma in the battle against dry eye disease (DED). OKYO and the FDA had an amicable meeting regarding pre-IND (Investigational New Drug), where non-clinical and clinical development plans were discussed. And now OKYO is enroute to filing the IND for OK-101 by Q3/4 of 2022.
“The pain reducing feature of OK-101 offers the opportunity that our drug can potentially treat neuropathic corneal pain, a severe, chronic and debilitating disease for which there are no approved commercial treatments currently available” stated Raj Patil, PhD, Chief Scientific Officer of OKYO.
Ocular Diseases
The Pharma company is focused on developing drugs for:
- Dry Eye Disease – inflammation in the eyes due to lack of lubrication and moisture on the surface of the eye. More than 35% of people of 50 suffer from DED.
- Non-infectious Anterior Uveitis – inflammation in the iris which is the third leading cause of blindness
- Allergenic Conjunctivitis – allergic reaction which leads to inflamed conjunctiva. Upto 40% of the population of the planet suffer from pink eye.
- Ocular Pain – pain in the eyes due to trauma, infection, post-surgical, dry eye syndrome, uveitis, corneal abrasions or ulcers. Approximately 5 million people suffer from ocular pain every year.
Pipeline
There are only two drugs under development by OKYO Pharma:
- OK-101 – Used to aid DED, Uveitis & Allergic Conjunctivitis
- Development is at pre-clinical
- OK-201 – Used to help ocular pain
- Still under lead optimisation
